Trial · NCT06139796
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pharmacokinetics Darunavir | From enrollment to the end of treatment at 24 weeks | area under the concentration-time curve (AUC0-12) (Cohort A) |
| Primary | Pharmacokinetics Darunavir | From enrollment to the end of treatment at 24 weeks | area under the concentration-time curve (AUC0-24) (Cohort B) |
| Primary | Pharmacokinetics Darunavir | From enrollment to the end of treatment at 24 weeks | maximum plasma concentration (Cmax) |
| Primary | Pharmacokinetics Darunavir | From enrollment to the end of treatment at 24 weeks | 12 hours or 24 hours post dose concentrations (C12 or C24) |
| Primary | Safety events | From enrollment to the end of treatment at 24 weeks | serious adverse events (SAEs) |
| Primary | Safety events | From enrollment to the end of treatment at 24 weeks | adverse events (AEs) of Grade 3 or higher |
| Primary | Safety events | From enrollment to the end of treatment at 24 weeks | treatment related AEs |
| Primary | Safety events | From enrollment to the end of treatment at 24 weeks | AEs leading to treatment discontinuation or modification |
| Secondary | Acceptability | From enrollment to the end of treatment at 24 weeks | Questionnaire |
| Secondary | Efficacy of treatment | From enrollment to the end of treatment at 24 weeks | HIV-1 RNA \<50 c/mL and \<400 c/mL |
| Secondary | Efficacy of treatment | From enrollment to the end of treatment at 24 weeks | Occurrence of a new or recurrent WHO clinical stage 3 or 4 event |
| Secondary | Efficacy of treatment | From enrollment to the end of treatment at 24 weeks | Change in CD4 cell count and percentage from baseline to week 24 |
| Secondary | Pharmacokinetics Ritonavir | From enrollment to the end of treatment at 24 weeks | RTV PK parameters and DRV unbound concentrations |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06139796/registered